This means the body produces less natural steroid hormones, which can lead to fatigue, weakness, and other systemic symptoms
Patient Safety Continuing appetite-suppressing medication at very low BMIs may increase the risk of: Excessive or unintended weight loss Nutritional deficiencies Lean muscle loss Hormonal disruption Disordered eating patterns The BMI 22 kg/m threshold acts as a safety boundary
Understanding potential interactions between prescription medications and supplements is essential for safe, effective treatment
PubMed CrossRef Hegeds C, Kovcs D, Kiss R, et al
5 Of note, orforglipron significantly improved waist circumference, systolic blood pressure, triglyceride levels, and nonhigh-density lipoprotein cholesterol levels compared with placebo
Feature Building companies for unmet needs July 16, 2026 Charles Craiks entrepreneurial journey shows how curiosity-driven chemistry led to multiple biotech companies, and how tools, collaboration and unmet clinical needs shape when academic discoveries move from the lab toward real-world impact